psychedelics-investing Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
psychedelics-investing Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
psychedelics-investing Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression and Clinical Trial Plans for Post-Traumatic Stress Disorder on January 7, 2026, 10:00am ET
psychedelics-investing Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
psychedelics-investing NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
psychedelics-investing Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
psychedelics-investing Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
psychedelics-investing Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
psychedelics-investing Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
psychedelics-investing Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
